Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5406-5408

  Rotem, Shahar ^a   Bar Haim, Erez ^a   Cohen, Hila ^a   Elia, Uri ^a   Ber, Raphael ^a   Shafferman, Avigdor ^a   Cohen, Ofer ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DOXYCYCLINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FRANCISELLA TULARENSIS; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; THERAPY DELAY; TULAREMIA;

ANIMALS; CIPROFLOXACIN; DOXYCYCLINE; FEMALE; FRANCISELLA TULARENSIS; MICE; MICE, INBRED BALB C; TULAREMIA;

EID: 84866327588     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01104-12     Document Type: Article

References (19)

1. Aranda EA. 2001. Treatment of tularemia with levofloxacin. Clin. Microbiol. Infect. 7:167-168.
2. Arav-Boger R. 2000. Cat-bite tularemia in a seventeen-year-old girl treated with ciprofloxacin. Pediatr. Infect. Dis. J. 19:583-584. (Pubitemid 30409496)
3. Bar-Haim E, et al. 2008. Interrelationship between dendritic cell trafficking and Francisella tularensis dissemination following airway infection. PLoS Pathog. 4:e1000211. doi:10.1371/journal.ppat.1000211.
4. Craven RR, Hall JD, Fuller JR, Taft-Benz S, Kawula TH. 2008. Francisellatularensis invasion of lung epithelial cells. Infect. Immun. 76:2833-2842.
5. Dennis DT, et al. 2001. Tularemia as a biological weapon: medical and public health management. JAMA 285:2763-2773. (Pubitemid 32525374)
6. Ellis J, Oyston PC, Green M, Titball RW. 2002. Tularemia. Clin. Microbiol. Rev. 15:631-646. (Pubitemid 41184082)
7. Enderlin G, Morales L, Jacobs RF, Cross JT. 1994. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin. Infect. Dis. 19:42-47. (Pubitemid 24227033)
8. Horzempa J, et al. 2011. Invasion of erythrocytes by Francisella tularensis. J. Infect. Dis. 204:51-59.
9. Limaye AP, Hooper CJ. 1999. Treatment of tularemia with fluoroquinolones: two cases and review. Clin. Infect. Dis. 29:922-924. (Pubitemid 30256390)
10. Markel G, et al. 2010. The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis. PLoS One 5:e11176. doi:10.1371/journal.pone.0011176.
11. Overholt EL, et al. 1961. An analysis of forty-two cases of laboratory-acquired tularemia. Treatment with broad spectrum antibiotics. Am. J. Med. 30:785-806.
12. Oyston PC, Sjostedt A, Titball RW. 2004. Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat. Rev. Microbiol. 2:967-978. (Pubitemid 39562535)
13. Piercy T, Steward J, Lever MS, Brooks TJ. 2005. In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice. J. Antimicrob. Chemother. 56:1069-1073. (Pubitemid 43009822)
14. Russell P, Eley SM, Fulop MJ, Bell DL, Titball RW. 1998. The efficacy of ciprofloxacin and doxycycline against experimental tularaemia. J. Antimicrob. Chemother. 41:461-465. (Pubitemid 28167505)
15. Sawyer WD, Dangerfield HG, Hogge AL, Crozier D. 1966. Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriol. Rev. 30:542-550.
16. Scheel O, Reiersen R, Hoel T. 1992. Treatment of tularemia with ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 11:447-448.
17. Sjostedt A. 2006. Intracellular survival mechanisms of Francisella tularensis, a stealth pathogen. Microbes Infect. 8:561-567. (Pubitemid 43214620)
18. Sjostedt A. 2007. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann. N. Y. Acad. Sci. 1105:1-29. (Pubitemid 47507090)
19. Steward J, Piercy T, Lever MS, Simpson AJ, Brooks TJ. 2006. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin. Int. J. Antimicrob. Agents 27:439-443.